MHRA approves Krystal’s Vyjuvek
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""]The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the use of B-Vec (Vyjuvek) developed by Krystal Biotech Inc., for the treatment of Dystrophic Epidermolysis Bullosa in patients from birth onwards. B-Vec is a topical gene therapy...